Beta-blockers for the treatment of problematic hemangiomas

Abstract

French

Objective

To examine treatment indications, efficacy and side effects of oral beta-blockers for the treatment of problematic hemangiomas.

Methods

A retrospective review of patients with hemangiomas presenting to the Alberta Children's Hospital Vascular Birthmark Clinic (Calgary, Alberta) between 2009 and 2011 was conducted. The subset of patients treated with oral beta-blockers was further characterized, investigating indication for treatment, response to treatment, time to resolution of indication, duration of treatment, occurrence of rebound growth and side effects of therapy.

Results

Between 2009 and 2011, 311 new patients with hemangiomas were seen, of whom 105 were treated with oral beta-blockers. Forty-five patients completed beta-blocker treatment while the remainder continue to receive therapy. Indications for treatment were either functional concerns (68.6%) or disfigurement (31.4%). Functional concerns included ulceration (29.5%), periocular location with potential for visual interference (28.6%), airway interference (4.8%), PHACES syndrome (3.8%), auditory interference (0.95%) and visceral location with congestive heart failure (0.95%). The median age at beta-blocker initiation was 3.3 months; median duration of therapy was 10.6 months; and median maximal treatment dose was 1.5 mg/kg/day for propranolol and 1.6 mg/kg/day for atenolol. Ninety-nine patients (94.3%) responded to therapy with size reduction, colour changes, softened texture and/or healing of ulceration. Rebound growth requiring an additional course of therapy was observed in 23 patients. Side effects from beta-blockers included cool extremities (26.7%), irritability (17.1%), lower gastrointestinal upset (14.3%), emesis (11.4%), hypotension (10.5%), poor feeding (7.6%), lethargy (4.8%), bronchospasm (0.95%) and rash (0.95%). Side effects did not result in complete discontinuation of beta-blocker treatment in any case; however, they prompted a switch to a different beta-blocker preparation in some cases. Resolution of the primary indication, requiring a median time of three months, occurred in 87 individuals (82.9%).

Conclusions

Treatment of infantile hemangiomas with oral beta-blocker therapy is highly effective and well tolerated, with more than 94% of patients demonstrating a response to treatment and 90% showing resolution of the primary functional indication for treatment.

Keywords

Beta-blocker Hemangioma Indications Propranolol Side effects Treatment efficacy

Get full access to this article

View all access options for this article.

References

Mulliken

Young

. Vascular birthmarks: Hemangiomas and Vascular Malformations. Philadelphia: WB Saunders, 1988; 41–62.

Mousa

Kues

Haas

. Successful treatment of a large hemangioma with propranolol. J Germ Soc Derm 2010; 8: 184–6.

Gampper

Morgan

. Vascular anomalies: Hemangiomas. Plast Reconstr Surg 2002; 110: 572–85.

Bruckner

Frieden

. Infantile hemangiomas. J Am Acad Dermatol 2006; 55: 671–82.

Christison-Lagay

Fishman

. Vascular anomalies. Surg Clin N Am 2006; 86: 393–s425.

Arneja

Gosain

. Vascular malformations. Plast Reconstr Surg 2008; 121: 195e–206e.

Leauté-Labrèze

Prey

Ezzedine

. Infantile haemangioma: Part II. Risks, complications and treatment. J Eur Acad Dermatol Venereol 2011; 25: 1254–60.

Leauté-Labrèze

de la Roque

Hubiche

Boralevi

Thambo

J-B

Taieb

. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649–51.

Itinteang

Brasch

Tan

Day

. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg 2010; 64: 759–65.

10.

Iaccarino

Ciccarelli

Soriento

. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptors overexpression: A novel role for the endothelial adrenergic system. Circ Res 2005; 97: 1182–9.

11.

Storch

Hoeger

. Propranolol for infantile haemangiomas: Insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269–74.

12.

Frieden

Drolet

. Propranolol for infantile hemangiomas: Promise, peril, pathogenesis, Pediatr Dermatol 2009; 26:642–4.

13.

Sharma

Fraulin

FOG

Harrop

McPhalen

. The opportunities and obstacles in developing a vascular birthmark database for clinical and research use. Can J Plast Surg 2011; 19: 122–4.

14.

Fraulin

FOG

Flannigan

Sharma

. The epidemiological profile of the Vascular Birthmark Clinic at the Alberta Children's Hospital. Can J Plast Surg 2012; 20: 67–70.

15.

Hong

Fischer

. Propranolol for recalcitrant ulcerated hemangioma of infancy. Ped Dermatol 2012; 29: 64–67.

16.

Bernabeau-Wittel

Pereyra-Rodriguez

Mantrana-Bermeja

. Propranolol for the treatment of severe hemangiomas of infancy: Results from a series of 28 patients. Actas Dermosifiliogr 2011; 102: 510–6.

17.

Buckmiller

Munson

Dyamenahalli

. Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center. Laryngoscope 2010; 120: 676–81.

18.

Manunza

Syed

Laguda

. Propranolol for complicated infantile haemangiomas: A case series of 30 infants. Br J Dermatol 2010; 162: 46–8.

19.

Qin

Liu

. [Treatment of infantile hemangiomas with low-dose propranolol: Evaluation of short-term efficacy and safety] Zhonghua Yi Xue Za Zhi 2009; 89:3130–4.

20.

Fuchsmann

Quintal

M-C

Giguerre

. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngo Head Neck Surg 2011; 137: 471–8.

21.

Schupp

Kleber

J-B

Gunther

Holland-Cunz

. Propranolol therapy in 55 infants with infantile hemangioma: Dosage, duration, adverse effects, and outcome. Ped Dermatol 2011; 28: 640–4.

22.

Sans

Dumas de la Roque

Berge

. Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics 2009; 124: 423–31.

23.

Haider

Pager

Neely

. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS 2010; 14: 251–6.

24.

Claerhout

Buijsrogge

Delbeke

. The use of propranolol in the treatment of periocular infantile haemangiomas: A review. Br J Ophthal 2011; 95: 1199–202.

25.

Blatt

Morrell

Buck

. Beta-blockers for infantile hemangiomas: A single-institution experience. Clin Pediat 2011; 50: 757–63.

26.

De Graaf

Breur

Raphael

. Adverse effects of propranolol when used in the treatment of hemangiomas: A case series of 28 infants. J Am Acad Dermatol 2011; 65: 320–7.

27.

Raphael

de Graaf

Breugem

. Atenolol: A promising alternative to propranolol for the treatment of hemangiomas. J Am Acad Dermatol 2011; 65: 420–1.

28.

Hogeling

Adams

Wargon

. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128: 259–66.

29.

Cushing

Boucek

Manning

. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head Neck Surg 2011; 144: 78–84.

30.

Al Dhaybi

Superstein

Milet

. Treatment of periocular infantile hemangiomas with propranolol: Case series of 18 children. Ophthalmology 2011; 118: 1184–8.

31.

Schiestl

Neuhaus

Zoller

. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr 2011; 170: 493–501.

32.

Holmes

Mishra

Gorst

Liew

. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesth Surg 2011; 64: 445–51.

33.

Missoi

Lueder

Gibertson

Bayliss

. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol 2011; 129: 899–903.

34.

Bagazgoitia

Torrelo

Gutierrez

. Propranolol for infantile hemangiomas. Pediat Dermatol 2011; 28: 108–14.

35.

Zvulunov

McCuaig

Frieden

. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: A multicenter retrospective study. Ped Derm 2011; 28: 94–8.

36.

George

Sharma

Jacobson . Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 2004; 140: 963–9.

37.

Baselga

. Past, present, and future of propranolol for hemangiomas of infancy. Actas Dermosifiliogr 2011; 102: 484–6.

38.

Price

Lattouf

Baum

. Propranolol vs corticosteroids for infantile hemangiomas: A multicenter retrospective analysis. Arch Dermatol 2011; 147: 1371–6.

39.

Peridis

Pilgrim

Athanasopolous

Parpounas

. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Ped Otorhinolaryngol 2011; 75: 455–60.